5 Key Takeaways
-
1
The port delivery system with ranibizumab (Susvimo) showed sustained vision outcomes over 5 years for neovascular age-related macular degeneration (nAMD).
-
2
Approximately half of the participants maintained 20/40 vision or better, with an average decline in best-corrected visual acuity of about 7 letters.
-
3
The study reported a low endophthalmitis rate of 2.6%, with improved safety following a procedural update in June 2020.
-
4
95% of patients were able to go 6 months between PDS refills without needing rescue treatment, indicating effective disease management.
-
5
The Portal study represents the largest prospective cohort of nAMD patients followed for 5 years, highlighting the benefits of continuous maintenance therapy.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.